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Bronchial neuroendocrine tumors (NET) are classified into well-differentiated typical carcinoids (TC), atypical carcinoids (AC),
large cell neuroendocrine carcinomas (LCNEC), and small cell lung carcinomas (SCLC). We retrospectively reviewed and
analyzed the diagnostic and therapeutic aspects, follow-up data, and outcomes of all patients diagnosed with a bronchial NET
from 1995 to 2015 at our institution. Patients with LCNEC or SCLC were excluded due to the biological and clinical differences
from the other bronchial NET. The clinical, laboratory, imaging, treatment, and follow-up data were collected and analyzed
keeping in mind the recently published international recommendations. Forty-six patients were included in the study. Of these,
37 had a TC and 5 an AC. In 4 patients, the histological characterization was inadequate. Forty-four patients underwent surgery.
Four patients developed metastatic disease. Interestingly, 14 patients had one or more other tumors diagnosed at some stage and
3 of them had three different tumors. A total of 7 patients died. The analysis of the laboratory and pathology assessment
identified some inconsistencies when compared to the international recommendations. Although the treatment of bronchial
NET at our institution was consistent with the successively published recommendations, it appears that the diagnostic process
and the follow-up surveillance were not. We think that a systematic multidisciplinary approach might improve bronchial NET
patient care. A relatively high rate of occurrence of a second, or also a third, non-NET tumor was observed, though the
statistical value of such observation could not be exhaustively elucidated in this numerically limited patient population. In our
opinion, the observed high rate of second malignancies in this patient cohort highlights the necessity of optimizing the follow-
up of the bronchial NET patients, also considering the very good survival rate achieved with regard to the bronchial NET.
1. Introduction
Bronchial neuroendocrine tumors (NET) belong to the het-
erogeneous group of rare neoplasms originating from the
enterochromaffin cells which are diffusely distributed in the
body [1]. The incidence rate of bronchial carcinoids ranges
from 0.2 to 2/100,000 population per year in both US and
European countries [2]. The incidence of these tumors has
increased significantly over the past 30 years, at a rate of
approximately 6% per year, due to improved awareness and
available diagnostics [2]. The World Health Organization
(WHO) identifies four histological variants of bronchial
NET, namely, well-differentiated typical carcinoids (TC),
atypical carcinoids (AC), large cell neuroendocrine carcino-
mas (LCNEC), and small cell lung carcinomas (SCLC) [3].
The most relevant aspect of the 2015 WHO classification in
comparison to the previous classification is represented by
the separation of carcinoids (either typical or atypical) from
LCNEC and SCLC, which are grouped together [3, 4].
Depending on their grade of malignancy, bronchial NET
can also be classified into low grade TC, intermediate grade
AC, and high grade LCNEC/SCLC [3]. TC usually grow
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slowly and do not often spread beyond the lungs. AC grow
faster than the typical tumors and are more likely to metasta-
size to other organs. LCNEC, a rare form of poorly differen-
tiated malignant tumor, are similar to SCLC in terms of
prognosis and treatment. SCLC represent one of the most
rapidly growing types of cancer and determine a poor prog-
nosis [5]. SCLC are NET from a biological point of view
but their behavior is usually very aggressive and, con-
versely, the management of these lesions also differs very
much from the other bronchial NET [6]. SCLC and
LCNEC are associated with heavy smoking and recent
reports confirm the role of smoking in AC development
as well [7, 8]. TC and AC are usually sporadic tumors;
however, rare familial cases have been reported [9]. They
may be associated with multiple endocrine neoplasia type
1 in less than 5% of patients [10]. The occurrence of car-
cinoid syndrome or symptoms of Cushing’s syndrome are
rare and occurrence of tumor-associated acromegaly is
pretty much anecdotal [2]. The clinical picture may
include symptoms such as cough, haemoptysis, dyspnoea,
chest pain, or wheezing, or could be even completely
asymptomatic [11].
Computed tomography (CT) scan with contrast is the
gold standard for bronchial NET diagnostic imaging, but
pathological examination is mandatory for their correct clas-
sification [2]. Ki-67 proliferation index helps to distinguish
well-differentiated tumors from the poorly differentiated
ones [5]. The major pathological biomarkers are chromogra-
nin A, synaptophysin, and CD56 [12]. Flexible bronchoscopy
is indicated in all the central forms of bronchial NET, while
rigid bronchoscopy may be preferred in patients at high risk
for bleeding [2]. Nuclear medicine techniques (octreoscan,
gallium-68 DOTA positron emission tomography) are more
specific than conventional imaging, enable whole-body
imaging for staging, and may help to predict the response
to peptide receptor radionuclide therapy (PRRT), if neces-
sary at any stage of the therapeutic management [11].
Surgical resection is the treatment of choice for bronchial
NET [1, 2, 13, 14]. In cases with advanced disease, cytoabla-
tive procedures such as locoregional therapy and PRRT may
represent effective palliative therapeutic options [15]. Cyto-
toxic treatment has been the standard for aggressive bron-
chial NET, although the available chemotherapy regimens
demonstrate a limited effect [2]. The inconsistencies between
the recommendations for systemic therapies, especially radi-
ation and chemotherapy, result in a lack of consensus on a
standardized treatment for unresectable disease [16].
Somatostatin analogs are considered as first-line treatment
for patients with advanced unresectable bronchial NET with
low proliferation index and positive octreoscan. Two large
studies (PROMID and CLARINET) have demonstrated an
improved progression-free survival in patients with a diges-
tive tract NET treated with somatostatin analogs [17, 18].
However, there is no extensive and conclusive data on the
anti-proliferative effects of somatostatin analogs in bronchial
NET to date. Indeed, the knowledge and expertise regarding
bronchial NET internationally has developed much more
slowly than that of NET of the digestive tract in the last
decade and this issue highlights the need to focus more
extensively on this area with the ultimate goal of improving
patient care.
In this retrospective study, we have analyzed the diagnos-
tic and therapeutic approach to the patients with TC and AC
in our institution in the last 20 years and compared them
with the recommendations recently published for assessing
the quality of the clinical service provided so far. In the last
twenty years, a structured care for the management of bron-
chial NET patients including a dedicated multidisciplinary
approach did not exist at our institution. Moreover, we have
assessed the clinical outcomes on the basis of patient records
and recorded the most relevant findings.
2. Patients and Methods
One hundred and seven patients with a bronchial NET have
been diagnosed, treated, or followed-up at our institution
from 1st January 1995 to 31st December 2015. Sixty patients
have been excluded as they had SCLC and one patient has
been excluded as she had a LCNEC.We excluded the patients
with LCNEC or SCLC due to the biological and clinical dif-
ferences between these tumors and the other bronchial
NET. No other exclusion criteria applied. Thus, forty-six
patients with TC or AC have been finally included in our
study. The most relevant anthropometric data of the patients
and the general information regarding their inpatient or out-
patient care at our institution were recorded in an electronic
database, built for the scope. We have collected laboratory,
imaging, treatment, and follow-up data from patient charts
and the electronic system of the hospital. We analyzed these
findings and compared them with the international recom-
mendations published in 2015 [2]. Moreover, we have
divided the patients in chronological subgroups and analyzed
the differences in terms of professional practice. The aim was
to assess the management of patients with a bronchial NET
in the last twenty years and identify the weakest areas in
the management of these patients with the ultimate goal of
improving future patient care. The blood tests were per-
formed in the laboratory of our institution, with the excep-
tion of chromogranin A that was sent abroad (Laboratory
of Neuroendocrinology, Royal Victoria Hospital, Belfast,
UK). The majority of the radiological investigations were
done at our institution. When the patient had imaging done
elsewhere, we collected and reviewed the scans at the radiol-
ogy department of our institution. The pathology specimens
have been processed and analyzed at our institution and if the
specimen was collected elsewhere, the pathology block was
subsequently processed and reviewed at our institution.
With regard to the chronological subgroup analysis of the
professional practice, we have applied chi-squared tests for
testing the differences between the periods with a statistically
sufficient number of patients. Since a quite large number of
other tumors appeared in our patient population, a Bayesian
Fisher exact test on contingency tables was performed to
investigate the proportion of occurrences of the second and
third tumors, and by using simple uniform priors on the pro-
portions, the posterior distribution of the beta-binomial
model was assessed. Unfortunately, the comparison of the
data on the occurrences of the second and third tumors with
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the corresponding data from the general oncological popula-
tion in Ireland was not possible due to the unavailability of a
national database record.
This study is compliant with the declaration of Helsinki
of the World Medical Association and as per its audit nature
did not require ethical committee approval.
3. Results
Forty-six consecutive patients were collected. Twenty-three
patients were female (48.9%), and twenty-four were male
(51.1%). The mean age was 55 years (range: 15–82 years).
Thirty-seven patients had a histological diagnosis consistent
with TC (80.4%) and five with AC (10.9%) (Table 1). Four
patients were diagnosed with a bronchial NET but the histo-
logical characterization of their specimens was inadequate
for a more precise definition (8.7%).
Four patients with a bronchial NET had metastatic
disease at some stage (8.7%). Three of them had evidence
of metastases already at the time of the diagnosis of bron-
chial NET. Two of them had lymph node metastases and
underwent lymphadenectomy, two patients had liver
involvement (both non-treated due to poor prognosis),
and one of them later developed lung recurrence of the
NET. The patient with liver metastases and lung reoccur-
rence of the tumor was apparently free from metastatic
disease at the time of the bronchial NET diagnosis (AC).
Chest X-ray, chest CT, and bronchoscopy before surgery
(or decision not to operate) were performed in 100% of the
patients. Specimens for histological examination were avail-
able for all patients. During the follow-up, chest X-ray was
done in 93.5% and CT in 65.2% of the patients. However,
these investigations have not been carried in a timely fashion
according to the international recommendations but were
performed mostly in a random way, without the identifica-
tion of a defined follow-up pattern. On the contrary, a lack
of consistency in the laboratory (chromogranin A never
assessed) and pathology (Ki-67 assessed in 34.8%, mitotic
count in 58.7%, and chromogranin A in 54.3% of the
patients, synaptophysin in 60.9% of the patients) findings
before/at the time of surgery as well as in the laboratory
and endoscopic assessment during the follow-up (chromo-
granin A assessed in 2.2% and bronchoscopy performed in
8.7% of the patients) was identified (Table 2). At histology,
chromogranin A was positive in 20 patients (80.0%) and neg-
ative in five patients (20.0%), while synaptophysin was posi-
tive in every specimen tested for. Other histological markers
have been randomly checked (CD56 — n = 4, cytokeratins
AE1/3 — n = 9, Leu-7 — n = 2, CAM — n = 1, and CK7 —
n = 1) and were positive in every specimen tested for. 18F-
FDG positron emission tomography (18F-FDG PET) was
carried out in eighteen patients (39.1%) and was positive in
seventeen patients and negative in one of them. All eighteen
patients underwent pre-operative 18F-FDG PET and nobody
underwent a post-operative 18F-FDG PET. Octreoscan was
carried out in six patients only (13.0%). Three of them had
a somatostatin receptor-positive tumor. None of the patients
who had pre-operative octreoscan underwent also a post-
operative octreoscan.
Forty-four patients (95.6%) underwent surgery. One of
the patients was not treated as she was unfit for surgery or
systemic treatments because of her poor lung function and
did not receive any treatment (Table 3). One patient with
synchronous squamous cell carcinoma of the lung was
treated with both chemotherapy (5-fluorouracil with temo-
zolomide) and radiotherapy.
The analysis of the professional practice among the chro-
nological subgroup of patients was possible only between the
chronological groups 2006–2010 and 2011–2015 (Tables 4, 5,
and 6). There is no evidence to suggest any difference
between these two time frames (p-value= 0.6394). We could
not compare the other time frames due to the insufficient
number of patients (<5) in each subgroup.
Table 1: Characteristics of bronchial NET patients diagnosed,
treated, or followed-up at our institution from 1st January 1995 to
31st December 2015 (n = 46).
Age at the time of diagnosis
(mean± SD and range)
55.2± 16.0 years
15–82 years
Gender (n and % females, n and % males)
22 females (47.8%)
24 males (52.2%)




Metastatic disease (n and %) 4 (8.7%)
n: number of patients, SD: standard deviation.
Table 2: Biochemistry, imaging, bronchoscopy, and pathology
findings in bronchial NET patients diagnosed, treated, or followed-
up at our institution from 1st January 1995 to 31st December
2015 (n = 46). Treatment refers to surgery, chemotherapy, or
radiotherapy.




Ki-67 (histology) 16 (34.8%)
Mitotic count (histology) 27 (58.7%)
Synaptophysin (histology) 28 (60.9%)
Chromogranin A (histology) 25 (54.3%)
















n: number of patients.
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At the time of the data collection, thirty-eight patients
were alive (82.6%) and seven patients had died (15.2%),
among which three died because of recurrence and/or metas-
tases of bronchial NET. Four patients died as a consequence
of other clinical issues (colorectal cancer, stroke). The out-
come of one patient is unknown.
Fourteen patients (30.4%) also had one or more other
tumors diagnosed during the observation time and three of
them had a total of three tumors identified (Table 7). The first
of these three patients had TC, right renal cancer, and benign
cystic parotid tumor. The second patient had AC, adenocar-
cinoma of the lung, and colorectal cancer. In the third case
the patient had TC, melanoma, and a basal cell carcinoma.
Five patients (29.4%) were diagnosed with another tumor
before the diagnosis of the bronchial NET (over six months),
and eight patients (47.1%) had synchronous tumors (within
6 months before or after the diagnosis of bronchial NET).
Four patients (23.5%) had metachronous tumors (diagnosed
over 6 months from the diagnosis of bronchial NET)
(Table 8). Among the non-NET tumors, we had found one
squamous cell carcinoma excised from the cheek, two colo-
rectal cancers (the first tumor surgically resected and the
second tumor resected and treated with adjuvant chemother-
apy), one metastatic squamous cell carcinoma of unknown
primary treated with radical axillary lymphadenectomy and
subsequent adjuvant radiotherapy, three lung squamous cell
carcinomas (one treated with upper lobectomy and adjuvant
chemotherapy, one with upper lobectomy, and one with
chemo-radiotherapy), two renal cancers which underwent
nephrectomy, a benign cystic tumor of the parotid which
was removed surgically, a lung adenocarcinoma treated with
lower lobectomy, a papillary thyroid cancer treated with thy-
roidectomy, an atrial myxoma which was resected, a breast
cancer treated surgically, an ovarian cancer treated with
chemo-radiotherapy, a melanoma which was resected, and
a basal cell carcinoma excised from the pre-auricular area.
As per our statistical model based on the observed data, there
is a 95% probability that the difference between the propor-
tion of second tumor occurrence and the proportion of third
tumor occurrence falls in the range between −0.283 and
0.287, meaning that there is no significant difference between
the two proportions (Figure 1).
4. Discussion
The scientific knowledge regarding bronchial NET has
increased more slowly than that of NETs of the digestive tract
over the last couple of decades. Only recently have expert
recommendations for the diagnosis and management of
bronchial NET been published [2]. It appears that both scien-
tists and physicians dealing with these tumors should aim to
increase awareness in the field and improve the management
of patients with bronchial NET. In this retrospective study,
we have analyzed the diagnostic and therapeutic approach
to patients with a bronchial NET in our institution in the last
20 years and compared the findings with the recently
published international recommendations.
From a diagnostic point of view, all patients with
bronchial NET should have plasma chromogranin A levels
assessed, which never happened in our patient series. At his-
topathology, Ki-67 and chromogranin A should be assessed
in all specimens; however, in our series these markers were
checked only in 34.8% and 54.3%, respectively. From a ther-
apeutic point of view, most patients have received the appro-
priate surgical management of their tumor. Another patient
with synchronous lung squamous cell carcinoma was treated
with both chemotherapy and radiotherapy and the main goal
was the treatment of her non-neuroendocrine neoplasm.
None of the patients received somatostatin analogs. Indeed,
none of them had carcinoid syndrome. It is noteworthy to
report that for most of the observation time the evidence of
an anti-proliferative effect of the somatostatin analogs was
still uncertain, while now, at least for most of the NETs aris-
ing from the digestive tract, this is a demonstrated corner-
stone. One patient in our series did not receive any
treatment as she was unfit for surgery and no other form of
therapy was prescribed due to her co-morbidities and poor
baseline. This patient had liver metastases and her final out-
come was poor. Considering the most recent evidence and
the international recommendations, she may have been a
candidate for treatment with somatostatin analogs. However,
in general terms, the therapeutic management of bronchial
NET in our institution appears to reasonably match with
international guidelines. In the follow-up, conventional
imaging should be carried out at 3 and 6 months and then
yearly in patients with TC, in association with the measure-
ment of circulating chromogranin A for the first 2 years.
Then, annual chest X-ray and CT every 3 years are recom-
mended. For patients with AC, closer monitoring is rec-
ommended and CT is advised at 3 months post-surgery,
then, every 6 months for 5 years, and later every year.
Bronchoscopy should be carried out on a routine basis
every 5–10 years for TC and 1–3 years for AC. In our
patient series, follow-up bronchoscopy was performed in
four patients (8.7%). Three of these patients had TC and
underwent bronchoscopy in one, five, and seven years,
respectively. One patient with inadequate histological char-
acterization of the specimen underwent bronchoscopy in
one year and did not undergo any further bronchoscopy
Table 3: Therapeutic management of bronchial NET patients
diagnosed, treated, or followed-up at our institution from 1st
January 1995 to 31st December 2015 (n = 46). One patient





Somatostatin analogs 0 (0%)
Interferon alpha 0 (0%)
Peptide receptor radionuclide therapy 0 (0%)
Radiotherapy 1 (2.2%)
Chemotherapy 1 (2.2%)
Locoregional therapy of distant metastases
(radiofrequency ablation, chemoembolization)
0 (0%)
No treatment 1 (2.2%)
n: number of patients.
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Table 4: Characteristics of bronchial NET patients managed at our institution divided in chronological time frames.
1995–2000 2001–2005 2006–2010 2011–2015
n = 5 n = 2 n = 20 n = 19
Age at the time of diagnosis (mean± SD and range) 57.6± 25.4 40.5± 36.1 54.7± 13.8 56.7± 14.1
15–82 15–66 27–76 21–73
Gender (n and % females, n and % males)
3 (60.0%) 1 (50.0%) 6 (30.0%) 12 (63.2%)
2 (40.0%) 1 (50.0%) 14 (70.0%) 7 (36.8%)
Tumor type (n and %)
Typical 3 (60.0%) 1 (50.0%) 18 (90.0%) 15 (78.9%)
Atypical 1 (20.0%) 0 (0%) 1 (5.0%) 3 (15.8%)
Unknown 1 (20.0%) 1 (50.0%) 1 (5.0%) 1 (5.3%)
Metastatic disease (n and %) 1 (20%) 0 (0%) 1 (5.0%) 2 (10.5%)
n: number of patients, SD: standard deviation.
Table 5: Biochemistry, imaging, bronchoscopy, and pathology findings in bronchial NET patients managed at our institution divided in
chronological time frames.
1995–2000 2001–2005 2006–2010 2011–2015
n = 5 n = 2 n = 20 n = 19
Chromogranin A (plasma)
0 (0%) 0 (0%) 0 (0%) 0 (0%)
0 (0%) 0 (0%) 1 (5.0%) 0 (0%)
KI-67 (histology) 0 (0%) 0 (0%) 3 (15.0%) 13 (68.4%)
Mitotic count (histology) 2 (40.0%) 0 (0%) 12 (60.0%) 13 (68.4%)
Synaptophysin (histology) 3 (60.0%) 0 (0%) 12 (60.0%) 13 (68.4%)
Chromogranin A (histology) 3 (60.0%) 0 (0%) 8 (40.0%) 14 (73.7%)
CD 56 (histology) 0 (0%) 0 (0%) 2 (10.0%) 9 (47.4%)
Bronchoscopy
5 (100%) 2 (100%) 20 (100%) 19 (100%)
0 (0%) 0 (0%) 3 (15.0%) 1 (5.3%)
CT
5 (100%) 2 (100%) 20 (100%) 19 (100%)
4 (80.0%) 1 (50.0%) 13 (65.0%) 12 (63.2%)
Chest X-ray
5 (100%) 2 (100%) 20 (100%) 19 (100%)
5 (100%) 2 (100%) 19 (95.0%) 17 (89.5%)
18F-FDG PET
0 (0%) 0 (0%) 10 (50.0%) 8 (42.1%)
0 (0%) 0 (0%) 0 (0%) 0 (0%)
Octreoscan
0 (0%) 0 (0%) 1 (5.0%) 3 (15.8%)
0 (0%) 0 (0%) 2 (10.0%) 0 (0%)
n: number of patients.
Table 6: Therapeutic management of bronchial NET patients managed at our institution divided in chronological time frames.
1995–2000 2001–2005 2006–2010 2011–2015
n = 5 n = 2 n = 20 n = 19
Surgery 5 (100%) 2 (100%) 20 (95.2%) 17 (89.5%)
Somatostatin analogs 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Interferon alpha 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Peptide receptor radionuclide therapy 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Radiotherapy 0 (0%) 0 (0%) 0 (0%) 1 (5.3%)
Chemotherapy 0 (0%) 0 (0%) 0 (0%) 1 (5.3%)
Locoregional therapy of distant metastases
(radiofrequency ablation, chemoembolization)
0 (0%) 0 (0%) 0 (0%) 0 (0%)
No treatment 0 (0%) 0 (0%) 0 (0%) 1 (5.3%)
n: number of patients.
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following this. During the follow-ups, chest X-ray was
done in 93.5% and chest CT in 65.2% of the patients,
but these investigations have been carried out randomly
in terms of timing, without evidence of a specific follow-
up strategy. In the laboratory follow-up, chromogranin A
was assessed in only one patient and for once only. These
findings suggest that the follow-up of bronchial NET
patients at our institution has been mostly inconsistent with
the current international recommendations [2]. However,
the relevance of follow-up in bronchial NET patients is a
matter of debate. Recently, a retrospective study tried to
determine the relevance of close post-resection surveillance
for bronchopulmonary carcinoids. Fifty-seven patients
underwent lung resection between 2006 and 2013, most of
them for TC (93%). Eighteen patients underwent post-
operative bronchoscopy surveillance without showing any
recurrence of the disease. A total of 146 follow-up CT scans
were performed on fifty-three patients and, again, no disease
recurrence was detected. As per the authors, on the base of
their findings, close surveillance following complete resection
of a TC is probably unnecessary [19].
The retrospective analysis of the diagnostic process and
follow-up of this cohort of patients in our institution in
the last twenty years showed a partial lack of consistency
in the laboratory and pathology assessment before treat-
ment and some inconsistencies in the laboratory and
imaging findings/endoscopic assessment during follow-up.
It appears that the main issue was represented by the tim-
ing of the restaging during the follow-up, together with
the performance of a complete assessment including an
exhaustive histological characterization. Possibly, the diag-
nostic and follow-up inconsistencies could be reduced by a
multidisciplinary approach [20, 21]. In concordance with
the recommendations, the management of bronchial NET
should be shared by the multidisciplinary team (MDT)
including oncologists, radiologists, pathologists, surgeons,
and internists (i.e., respiratory physicians and endocrinolo-
gists). In 2013, a study focusing on the impact of a sys-
tematic multidisciplinary approach on the management
of patients with gastroenteropancreatic (GEP) NET illus-
trated for the first time that the MDT approach noticeably
altered the diagnosis, the management, and the follow-up
of patients with GEP NET and moved the current practice
at that institution to the best international practice in the
short-term (18months) [20]. In our opinion, a multidisci-
plinary approach would lead to a similarly significant
improvement of the care also with regard to patients with
bronchial NET.
In the analysis of the patient subgroups divided per time
frames, we have not reported any statistical difference
regarding the diagnostic or therapeutic management of
the bronchial NET patients. Probably this is a consequence
of the limited number of patients, at least in part. Moreover,
since no guidance was available in the literature before
2015, we think that the bronchial NET patients were
simply managed following the personal expertise and
judgment of the caregiver physicians, with a subsequent
homogenization of the professional practice. In other coun-
tries with more developed NET services over the last two
decades, the management consistently evolved overtime,
also as a consequence of the revisions of the WHO classifi-
cation of bronchial NETs [22, 23].
Table 7: Contingency table showing the number of second tumors
diagnosed in patients with a bronchial NET and the number of third
tumors diagnosed in patients with a bronchial NET and a second
tumor.
2nd tumor 3rd tumor
Number of patients 46 14
Number of events (second / third tumor
occurrences)
14 3
Table 8: Other tumor types recorded in bronchial NET patients
diagnosed, treated, or followed-up at our institution from 1st
January 1995 to 31st December 2015 (n = 46).
Non-NET tumors that occurred in
patients with a bronchial NET
Number of patients
(and %)
Total number of patients with other tumors 14 (30.4%)
Total number of other tumors 17 (37.0%)







(i) Cheek squamous cell carcinoma
(ii) Colorectal cancer
(iii) Metastatic squamous cell
carcinoma of unknown primary
(iv) Lung squamous cell carcinoma
(v) Renal cancer





















n: number of patients.
−0.4 −0.2 0.0 0.2 0.4
Figure 1: Posterior probability distribution of the mean difference
between the proportion of occurrence of a second tumor and the
proportion of occurrence of a third tumor in our patient
population. The vertical lines are drawn at the boundaries of the
central 95% region of the posterior difference.
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Bronchial NET may develop in patients with a previous
history of cancer, especially of the respiratory tract, urogeni-
tal tract, or the skin [24]. Moreover, a second neoplasia may
occur in patients with a history of bronchial NET. As
reported in our case series, fourteen patients also had other
tumors, corresponding to the impressive rate of almost one
every three patients, and three of these patients had a total
of three tumors during their life. We defined the tumors
occurring within 6 months of the diagnosis of their bronchial
NET as synchronous tumors. The tumors occurring more
than 6 months after the diagnosis of bronchial NET have
been defined as metachronous [25]. A small number of
patients in our series had a non-NET neoplasia diagnosed
before the diagnosis of bronchial NET. The Irish national sta-
tistics show that 30,000 new cases of cancer are diagnosed on
average each year and this number is expected to rise to over
40,000 per year by 2020 [26]. A recent Italian epidemiological
study analyzed 3205 patients with bronchial carcinoid in the
period 1975–2011 and found a high frequency of second
tumors. In particular, synchronous thyroid tumors in
females and metachronous renal tumors and synchronous
bladder tumors in males were reported [27]. A retrospective
American study assessed the risk of second malignancies in
children and adolescents with a NET in the period 1945–
2012 and did not detect second primary malignancies during
the routine long-term follow-up of these patients [28]. How-
ever, the large majority of these patients had an appendiceal
NET and only a very few had a bronchial carcinoid. In the
USA, a study on the risk of a second cancer among survivors
from a previous cancer from 1992 to 2008 showed that nearly
one in twelve patients diagnosed with a common cancer
developed a second malignancy, the most common of which
was lung cancer [29]. The predisposition to other tumors in
patients with NET has been evaluated in the Danish Cancer
Registry among more than one thousand patients [30]. The
overall relative risk was not increased, but there was an excess
of some tumor types. In particular, thyroid cancer, brain
tumors, and non-Hodgkin’s lymphoma were recorded more
often than expected in the NET patient population. However,
these findings were affected by a wide confidence interval
related to the relatively small number of patients. There is
data on second cancers in patients with NET also from
Sweden [31], where the risk of synchronous tumors in the
NET patient population was increased. However, in this
study the timeframe of synchronicity was extended to 12
months. These neoplasms aremostly gastrointestinal cancers,
but also the incidence of second primaries in the lung, the
prostate, the kidney, and the endocrine system was increased.
The reason of the increased incidence of a second tumor
has not been fully elucidated yet. Of course, this may repre-
sent an incidental diagnosis during diagnostic or follow-up
investigations. Moreover, with a regular, ongoing follow-up
of the bronchial NET patients in a tertiary referral center, it
is likely that also standard cancer screening was carried out
in a more regular way than for the general population.
Finally, we cannot exclude the presence of proto-oncogene
mutations which may predispose the bronchial NET patients
to an additional oncological risk, though at the moment there
are no literature data supporting such hypothesis. However,
such findings support the relevance of an appropriate
follow-up of the patients with bronchial NET because they
may have a higher risk of development of second tumors.
We think that the relatively high rate of second malignancies
in our bronchial NET patient cohort emphasizes the need of
an optimization of the follow-up of the bronchial NET
patients, especially if we keep in mind the well-known find-
ings of good survival reported for the majority of the patients
with a bronchial NET. Moreover, it appears that large and
homogeneous international epidemiological studies address-
ing the risk of second neoplasms in NET patients, and in par-
ticular in bronchial carcinoid patients, are required based on
the suspicious though non-conclusive findings so far.
5. Conclusions
Although the therapeutic management of bronchial NET in
our institution appears to match reasonably with the interna-
tional recommendations, the diagnostic process and the
follow-up of these patients was not consistent. We think that
the optimization of care for patients with bronchial NET is
an absolute requirement at this stage and should mirror the
evolution of the care of GEP NET patients in the last two
decades. A systematic multidisciplinary approach would
likely improve the still inconsistent aspects of care of patients
with bronchial NET with the ultimate goal of improving their
clinical outcomes. Impressively, almost one in every three
bronchial NET patients in our series also had a second tumor
at some stage. Keeping together our findings and the litera-
ture, it appears that a careful follow-up of bronchial NET
patients is also required considering the emerging evidence
of a possible high risk of development of secondmalignancies
in this patient group, though larger and dedicated interna-
tional epidemiological studies are necessary for confirming
the suspicion rising from our retrospective study.
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